Published in Biomedicines on September 12, 2017
Exploring the full spectrum of macrophage activation. Nat Rev Immunol (2008) 26.08
Macrophage biology in development, homeostasis and disease. Nature (2013) 8.28
Macrophage activation and polarization: nomenclature and experimental guidelines. Immunity (2014) 7.26
The M1 and M2 paradigm of macrophage activation: time for reassessment. F1000Prime Rep (2014) 4.97
NF-κB, inflammation, and metabolic disease. Cell Metab (2011) 4.00
Transcriptome-based network analysis reveals a spectrum model of human macrophage activation. Immunity (2014) 3.94
Macrophages in rheumatoid arthritis. Arthritis Res (2000) 3.40
Properties of mouse and human IgG receptors and their contribution to disease models. Blood (2012) 2.53
Resolution of inflammation: an integrated view. EMBO Mol Med (2013) 2.01
Resolution of cutaneous inflammation after local elimination of macrophages. Nat Biotechnol (2000) 1.88
Ricin: structure, mode of action, and some current applications. FASEB J (1994) 1.82
Fc receptors and their interactions with immunoglobulins. Annu Rev Cell Dev Biol (1996) 1.79
Fc receptor-targeted therapies for the treatment of inflammation, cancer and beyond. Nat Rev Drug Discov (2012) 1.62
Signalling, inflammation and arthritis: NF-kappaB and its relevance to arthritis and inflammation. Rheumatology (Oxford) (2008) 1.59
Angiogenin: a review of the pathophysiology and potential clinical applications. J Thromb Haemost (2006) 1.45
Monoclonal antibodies that bind to distinct epitopes on Fc gamma RI are able to trigger receptor function. J Immunol (1989) 1.41
[The treatment of chronic inflammatory diseases with monoclonal antibodies against tumor necrosis factor: side effects, contraindications and precautions]. Ned Tijdschr Geneeskd (2002) 1.39
Emerging role of angiogenin in stress response and cell survival under adverse conditions. J Cell Physiol (2012) 1.38
Immunotoxins for leukemia. Blood (2014) 1.33
A recombinant immunotoxin against the tumor-associated antigen mesothelin reengineered for high activity, low off-target toxicity, and reduced antigenicity. Mol Cancer Ther (2012) 1.27
Humanized immunotoxins: a new generation of immunotoxins for targeted cancer therapy. Cancer Sci (2009) 1.24
Macrophage proinflammatory activation and deactivation: a question of balance. Adv Immunol (2010) 1.23
Antigen targeting to myeloid-specific human Fc gamma RI/CD64 triggers enhanced antibody responses in transgenic mice. J Clin Invest (1996) 1.23
Diphtheria toxin and Pseudomonas aeruginosa exotoxin A: active-site structure and enzymic mechanism. Curr Top Microbiol Immunol (1992) 1.21
How does infliximab work in rheumatoid arthritis? Arthritis Res (2002) 1.20
Granzymes at a glance. J Cell Sci (2006) 1.18
The role of tumor-associated macrophages in breast cancer progression (review). Int J Oncol (2013) 1.16
Functional characteristics of the high affinity IgG receptor, FcγRI. J Immunol (2011) 1.15
Crystal structure of Fcγ receptor I and its implication in high affinity γ-immunoglobulin binding. J Biol Chem (2011) 1.12
Binding of monomeric immunoglobulin G triggers Fc gamma RI-mediated endocytosis. J Biol Chem (1994) 1.12
Targeted liposomal drug delivery to monocytes and macrophages. J Drug Deliv (2010) 1.08
Angiogenin abolishes cell-free protein synthesis by specific ribonucleolytic inactivation of ribosomes. Proc Natl Acad Sci U S A (1987) 1.08
Pseudomonas exotoxin A: from virulence factor to anti-cancer agent. Int J Med Microbiol (2008) 1.05
Mouse and human FcR effector functions. Immunol Rev (2015) 1.04
The high-affinity human IgG receptor FcγRI (CD64) promotes IgG-mediated inflammation, anaphylaxis, and antitumor immunotherapy. Blood (2013) 1.03
Granzyme B-H22(scFv), a human immunotoxin targeting CD64 in acute myeloid leukemia of monocytic subtypes. Mol Cancer Ther (2008) 1.03
Much More than M1 and M2 Macrophages, There are also CD169(+) and TCR(+) Macrophages. Front Immunol (2015) 0.99
Presentation of phagocytosed antigens by MHC class I and II. Traffic (2012) 0.98
Decreased Fc receptor expression on innate immune cells is associated with impaired antibody-mediated cellular phagocytic activity in chronically HIV-1 infected individuals. Virology (2011) 0.97
Controversies in granzyme biology. Tissue Antigens (2012) 0.97
Secretion of functional anti-CD30-angiogenin immunotoxins into the supernatant of transfected 293T-cells. Protein Expr Purif (2003) 0.96
Cell-based therapy for acute organ injury: preclinical evidence and ongoing clinical trials using mesenchymal stem cells. Anesthesiology (2014) 0.94
Structural basis for binding of human IgG1 to its high-affinity human receptor FcγRI. Nat Commun (2015) 0.93
Microtubule-associated protein tau facilitates the targeted killing of proliferating cancer cells in vitro and in a xenograft mouse tumour model in vivo. Br J Cancer (2013) 0.92
The second and third extracellular domains of FcgammaRI (CD64) confer the unique high affinity binding of IgG2a. Mol Immunol (1998) 0.92
Macrophage-targeted therapy: CD64-based immunotoxins for treatment of chronic inflammatory diseases. Toxins (Basel) (2012) 0.91
Ricin inhibits activation of the unfolded protein response by preventing splicing of the HAC1 mRNA. J Biol Chem (2008) 0.91
Phase I clinical trial of the bispecific antibody MDX-H210 (anti-FcgammaRI x anti-HER-2/neu) in combination with Filgrastim (G-CSF) for treatment of advanced breast cancer. Br J Cancer (2003) 0.90
Granzyme M as a novel effector molecule for human cytolytic fusion proteins: CD64-specific cytotoxicity of Gm-H22(scFv) against leukemic cells. Cancer Lett (2013) 0.88
Selective elimination of synovial inflammatory macrophages in rheumatoid arthritis by an Fcgamma receptor I-directed immunotoxin. Arthritis Rheum (2003) 0.88
Targeted drug delivery to macrophages. Expert Opin Drug Deliv (2013) 0.88
Phase 1 trial of the novel bispecific molecule H22xKi-4 in patients with refractory Hodgkin lymphoma. Blood (2002) 0.88
Role of macrophages in the pathogenesis of atopic dermatitis. Mediators Inflamm (2013) 0.88
Construction and characterization of a humanized anti-gamma-Ig receptor type I (Fc gamma RI) monoclonal antibody. J Immunol (1995) 0.87
In vivo efficacy of the recombinant anti-CD64 immunotoxin H22(scFv)-ETA' in a human acute myeloid leukemia xenograft tumor model. Int J Cancer (2011) 0.87
A phase-I trial of the epidermal growth factor receptor directed bispecific antibody MDX-447 without and with recombinant human granulocyte-colony stimulating factor in patients with advanced solid tumors. Cancer Immunol Immunother (2007) 0.87
Gene therapy targeting nuclear factor-kappaB: towards clinical application in inflammatory diseases and cancer. Curr Gene Ther (2009) 0.86
CD64-directed immunotoxin inhibits arthritis in a novel CD64 transgenic rat model. J Immunol (2006) 0.85
Current status of monoclonal antibody therapy for the treatment of inflammatory bowel disease. Expert Rev Clin Immunol (2010) 0.85
Humanized mAb H22 binds the human high affinity Fc receptor for IgG (FcgammaRI), blocks phagocytosis, and modulates receptor expression. J Leukoc Biol (1997) 0.85
Therapeutic human monoclonal antibodies in inflammatory diseases. Methods Mol Biol (2014) 0.84
Clinical experience with CD64-directed immunotherapy. An overview. Cancer Immunol Immunother (1998) 0.83
Granzyme B-mediated apoptosis--the elephant and the blind men? Cell Death Differ (2004) 0.83
Efficacy of an adapted granzyme B-based anti-CD30 cytolytic fusion protein against PI-9-positive classical Hodgkin lymphoma cells in a murine model. Blood Cancer J (2013) 0.82
Novel angiogenin mutants with increased cytotoxicity enhance the depletion of pro-inflammatory macrophages and leukemia cells ex vivo. Cancer Immunol Immunother (2015) 0.82
Design of human granzyme B variants resistant to serpin B9. Proteins (2012) 0.82
Targeting CD64 mediates elimination of M1 but not M2 macrophages in vitro and in cutaneous inflammation in mice and patient biopsies. MAbs (2015) 0.82
Recombinant, ETA'-based CD64 immunotoxins: improved efficacy by increased valency, both in vitro and in vivo in a chronic cutaneous inflammation model in human CD64 transgenic mice. Br J Dermatol (2010) 0.81
Macrophages and cutaneous inflammation. Nat Biotechnol (2000) 0.81
Targeted ex vivo reduction of CD64-positive monocytes in chronic myelomonocytic leukemia and acute myelomonocytic leukemia using human granzyme B-based cytolytic fusion proteins. Int J Cancer (2014) 0.80
The inflammation theory of disease. The growing realization that chronic inflammation is crucial in many diseases opens new avenues for treatment. EMBO Rep (2012) 0.80
Angiogenin mutants as novel effector molecules for the generation of fusion proteins with increased cytotoxic potential. J Immunother (2015) 0.80
Monoclonal antibody 197 (anti-Fc gamma RI) infusion in a patient with immune thrombocytopenia purpura (ITP) results in down-modulation of Fc gamma RI on circulating monocytes. Br J Haematol (1996) 0.80
Clinical evaluation of the bispecific antibody MDX-H210 (anti-Fc gamma RI x anti-HER-2/neu) in combination with granulocyte-colony-stimulating factor (filgrastim) for treatment of advanced breast cancer. Cancer Immunol Immunother (1998) 0.79
Fully human MAP-fusion protein selectively targets and eliminates proliferating CD64(+) M1 macrophages. Immunol Cell Biol (2016) 0.79
Recombinant lipid-tagged antibody fragments as functional cell-surface receptors. Nat Med (2000) 0.78
Fcgamma receptor 1 (CD64), a target beyond cancer. Curr Pharm Des (2009) 0.78
Structural mechanism of high affinity FcγRI recognition of immunoglobulin G. Immunol Rev (2015) 0.77
Inflammation: cell recruitment versus local proliferation. Curr Biol (2011) 0.77
Reduction of activated macrophages after ischaemia-reperfusion injury diminishes oxidative stress and ameliorates renal damage. Nephrol Dial Transplant (2012) 0.77
Human MAP Tau Based Targeted Cytolytic Fusion Proteins. Biomedicines (2017) 0.76
Granzyme M: behind enemy lines. Cell Death Differ (2014) 0.75
CD64-directed microtubule associated protein tau kills leukemic blasts ex vivo. Oncotarget (2016) 0.75